Business · 23/08/2021Updated: 10/17/2026 · 1 min read
FDA Clears ORTHO-CEPT Oral Tablets for Continued Sale
Summary
The US Food and Drug Administration has ruled that ORTHO-CEPT 21- and 28-day oral tablets, containing desogestrel-ethinyl estradiol, were not withdrawn from sale due to safety or effectiveness concerns, allowing the drug to remain on the market.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →